Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

Lung Cancer

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 22 articles: HTML format

Single Articles

April 2025
1. O'KEEFE S, Wang Q
   ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non-small cell lung cancer.
   J Clin Invest. 2025;135:e191094.
   PubMed     Abstract available
   
   
   
2. WANG S, Guo H, Fukushima R, Terajima M, et al
   Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression.
   J Clin Invest. 2025;135:e189197.
   PubMed     Abstract available
   
   
   
3. JIAO M, Guo Y, Zhang H, Wen H, et al
   ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy response in non-small cell lung cancer.
   J Clin Invest. 2025;135:e181517.
   PubMed     Abstract available
   
   
   March 2025
4. SHEN S, Zhang Q, Wang Y, Chen H, et al
   Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS-mutant cancer models.
   J Clin Invest. 2025;135:e185278.
   PubMed     Abstract available
   
   
   February 2025
5. YU F, Zheng S, Yu C, Gao S, et al
   KRAS Mutants Confer Platinum Resistance by Regulating ALKBH5 Post-translational Modifications in Lung Cancer.
   J Clin Invest. 2025 Feb 4:e185149. doi: 10.1172/JCI185149.
   PubMed     Abstract available
   
   
   December 2024
6. LI D, Geng K, Hao Y, Gu J, et al
   Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.
   J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249.
   PubMed     Abstract available
   
   
   October 2024
7. HUANG Q, Tian N, Zhang J, Song S, et al
   Nonclassical action of Ku70 promotes Treg-suppressive function through a FOXP3-dependent mechanism in lung adenocarcinoma.
   J Clin Invest. 2024;134:e178079.
   PubMed     Abstract available
   
   
   September 2024
8. REEVES MQ
   Mapping the transcriptional evolution of human metastatic breast cancer.
   J Clin Invest. 2024;134:e183971.
   PubMed     Abstract available
   
   
   June 2024
9. PARDO L, Norman JC
   Targeting the secretory program of 3q-amplified lung cancers.
   J Clin Invest. 2024;134:e181798.
   PubMed     Abstract available
   
   
   May 2024
10. MILLS GB, Labrie M
    Enhancing anticancer activity of macrophages through rational drug combinations.
    J Clin Invest. 2024;134:e180512.
    PubMed     Abstract available
    
    
    April 2024
11. HAYASHI H, Chamoto K, Hatae R, Kurosaki T, et al
    Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
    J Clin Invest. 2024;134:e168318.
    PubMed     Abstract available
    
    
    
12. TAN AC, Cook SL, Khasraw M
    Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
    J Clin Invest. 2024;134:e179352.
    PubMed     Abstract available
    
    
    March 2024
13. VACCARO K, Allen J, Whitfield TW, Maoz A, et al
    Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
    J Clin Invest. 2024;134:e169315.
    PubMed     Abstract available
    
    
    
14. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    PubMed     Abstract available
    
    
    January 2024
15. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    PubMed     Abstract available
    
    
    
16. GHANBAR MI, Suresh K
    Pulmonary toxicity of immune checkpoint immunotherapy.
    J Clin Invest. 2024;134:e170503.
    PubMed     Abstract available
    
    
    December 2023
17. JING N, Zhang K, Chen X, Liu K, et al
    ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
    J Clin Invest. 2023;133:e168670.
    PubMed     Abstract available
    
    
    
18. WANG S, Iyer R, Han X, Wei J, et al
    CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    J Clin Invest. 2023;133:e167728.
    PubMed     Abstract available
    
    
    November 2023
19. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    PubMed     Abstract available
    
    
    October 2023
20. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    PubMed     Abstract available
    
    
    
21. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    PubMed     Abstract available
    
    
    
22. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.